Cadrenal Therapeutics Inc (CVKD): Bathi resik saben saham (EPS TTM)

Cadrenal Therapeutics (CVKD) relies on a US-based R&D infrastructure, utilizing external CDMO partners to minimize production risks. The company generates revenue from patents for anticoagulants tailored for patients with kidney pathologies. This 12-month EPS chart allows for an assessment of financial stability, with -4.94 representing the most recent level. The business is currently focused on the successful completion of Phase II trials for its innovative drug.
Rincian analitis lan laporan data perusahaan Cadrenal Therapeutics, Inc (CVKD)

For Cadrenal Therapeutics (CVKD), whose anticoagulant developments are protected by humanitarian consensus, financial stability is determined by capitalization efficiency. This metric aggregates annual net income, dividing it by the total number of shares to assess yield per share. By analyzing the fundamental TTM earnings per share, an investor separates real growth from market noise. This prevents overpaying for stagnation. This indicator confirms the investment attractiveness of the capital.